Abstract

Reo Hamaguchi*, Ryoko Narui, Hiromasa Morikawa and Hiromi Wada

Pyrimidine fluoride anticancer drugs are used for the treatment of various cancers, such as lung cancer, colorectal cancer, gastric cancer, and breast cancer. In particular, tegafur-uracil treatment is well established as a postoperative adjuvant chemotherapy for Non-Small Cell Lung Cancer (NSCLC) patients, although the effectiveness of treatment differs depending on the type of cancer cells and the state of progression. Some characteristics of cancer cells may be associated with their treatment responses to tegafur-uracil. First, the genomic profiles of cancer cells may affect their response to tegafur-uracil therapy, although it remains unclear as to what specific genomic profiles of NSCLCs are associated with favorable treatment outcomes. Second, the tumor microenvironment that is created by the unique metabolic characteristics of cancer cells and is known to be associated with cancer progression and drug resistance may also be associated with the treatment response to tegafur-uracil. However, further studies are required to clarify the specific factors that are associated with the treatment response of cancer cells to tegafur-uracil.